Home › Diseases, disorders & medical disciplines
The Multiple Myeloma Research Foundation
The Multiple Myeloma Research Foundation reported $36.5 million in revenue and $34.7 million in expenses for calendar year 2025. Of every $100 it spent, $78.94 went to program services, $3.44 to management and general costs and $17.62 to fundraising. Its largest source of revenue was contributions and grants: 72.9% of the total. The highest compensation it reported for one person was $568,410 (PRESIDENT & CEO). 41 people received more than $100,000 in reportable compensation. Revenue fell 17% between 2019 and 2025. Source: Form 990, 2025.
Where $100 of spending went
Calendar year 2025 · Form 990, Part IX, line 25 · total expenses $35MFor context, the median across 314 covered diseases, disorders & medical disciplines charities: $88.73 programs, $10.89 management, $0.38 fundraising (medians computed separately, so they may not sum to $100).
Where $100 of revenue came from
Calendar year 2025 · Form 990, Part VIII · total revenue $37MThe 990 scorecard · same measures for every charity, no grades
| Measure | 2025 | Median |
|---|---|---|
| Program services Part IX 25(B) ÷ 25(A) | 78.9% | 86.7% |
| Management & general Part IX 25(C) ÷ 25(A) | 3.4% | 10.6% |
| Fundraising Part IX 25(D) ÷ 25(A) | 17.6% | 0.4% |
| Fundraising cost per $1 of contributions Part IX 25(D) ÷ Part VIII 1h | $0.23 | $0.03 |
| Contributions & grants share of revenue Part VIII 1h ÷ 12 | 72.9% | 24.7% |
| Government grants share of revenue Part VIII 1e ÷ 12 | 0.0% | 0.6% |
| Program service revenue share Part VIII 2g ÷ 12 | 23.8% | 59.5% |
| Highest reported compensation Part VII-A, columns D–F | $568,410 | $391,657 |
| Highest compensation as share of expenses Part VII-A ÷ Part IX 25(A) | 1.64% | 1.45% |
| People paid over $100,000 Part VII, line 2 | 41 | 10 |
| Net assets, in months of expenses Part X 33(B) ÷ monthly expenses | 16.6 | 7.6 |
| Independent voting board members Part VI 1a–1b | 14 of 14 | 100.0% |
A median is context, not a target: hospitals, universities, food banks and grantmakers spend in very different ways. What these measures can and can't tell you.
What the money paid for, in its own words
2025 · Form 990, Part III · the three largest programs by expenseThe Multiple Myeloma Research consortium (mmrc), the clinical research subsidiary of the Multiple Myeloma Research foundation (mmrf), is a collaborative network of leading cancer centers driving cutting-edge clinical trials. The mmrf launched the horizon clinical trials program through the mmrc to drive progress for patients who need it most. Horizon trials use an adaptive platform design that allows researchers to test several treatments at the same time and add new options as data becomes available. In 2025, the horizon one trial focused on relapsed/refractory myeloma exceeded many of its…
Data helps drive every breakthrough in myeloma. By building and sharing large, high-quality datasets, the mmrf is creating a launchpad for the next wave of treatments, improvements in care, and, ultimately, cures. In 2025, the mmrf launched its next innovation in data sharing: the mmrf virtual labtm. Virtual lab is now myeloma's largest, most-comprehensive data-sharing platform and brings all the mmrf's data into one place. The platform and its robust data will empower researchers to ask bigger questions, test new hypotheses, and accelerate discoveries that improve outcomes for patients with…
The mac program provides $21 million over 3 years to create multicenter translational research teams across global medical centers. Each of these three-year multicenter translational projects aim to foster collaboration and advance compelling hypotheses that are ready for rapid testing in clinical trials, a critical step in the mmrf's urgent pursuit of a cure for each and every myeloma patient. The grants are focused on two critical areas of unmet need: optimizing first-line therapy for newly diagnosed high-risk myeloma and improving identification of high-risk smoldering myeloma (hr smm), an…
Highest reported compensation
2025 · Form 990, Part VII, Section A · roles as filed; names are in the filing, not here| Role | From this org | From related orgs | Other | Total |
|---|---|---|---|---|
| PRESIDENT & CEO Officer, 40.00 hrs/week | $534,635 | $0 | $33,775 | $568,410 |
| CHIEF SCIENTIFIC OFFICER Key employee, 40.00 hrs/week | $370,521 | $0 | $64,920 | $435,441 |
| MANAGING DIRECTOR, MIF Key employee, 40.00 hrs/week | $397,759 | $0 | $33,610 | $431,369 |
| CHIEF MISSION OFFICER Key employee, 40.00 hrs/week | $374,586 | $0 | $19,455 | $394,041 |
| SECRETARY, CAO & GENERAL COUNSEL Officer, 40.00 hrs/week | $287,214 | $0 | $48,042 | $335,256 |
| VP OF CLINICAL RESEARCH Key employee, 40.00 hrs/week | $244,190 | $0 | $58,555 | $302,745 |
| VP OF MARKETING Highest compensated employee, 40.00 hrs/week | $220,914 | $0 | $61,822 | $282,736 |
| SR DIRECTOR, STRATEGIC PARTNERSHIPS Highest compensated employee, 40.00 hrs/week | $189,544 | $0 | $57,601 | $247,145 |
41 people received more than $100,000 in reportable compensation from The Multiple Myeloma Research Foundation (Part VII, line 2). Compensation of current officers, directors and key employees totaled $3.2M (Part IX, line 5).
7 years of filings
Form 990, Parts I, VII, IX and X · each row is that year's own filing, linkedGovernance answers, as filed
2025 · the organization's own yes/no answers; explanations, if any, are in Schedule O of the filing · what each means- Voting board members, and how many are independent Part VI, lines 1a–1b14 · 14 independent
- Audited financial statements Part XII 2bYes
- Conflict-of-interest policy Part VI 12aYes
- Whistleblower policy Part VI 13Yes
- Document retention policy Part VI 14Yes
- Independent process for top executive pay Part VI 15aYes
- Board given the 990 before filing Part VI 11aYes
- Family or business ties among insiders Part VI 2Yes
- Aware of a significant diversion of assets Part VI 5No
- Excess benefit transaction with an insider Part IV 25aNo
- Loans to or from insiders outstanding Part IV 26No
- Lobbying, or a 501(h) election in effect Part IV 4No
- Over $15,000 of professional fundraising services Part IV 18No
- Over $10,000 of activity outside the U.S. Part IV 14bYes
- Employees Part I, line 580
- Volunteers Part I, line 6200
Largest outside contractors
2025 · Form 990, Part VII, Section B · businesses only| ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI Biotechnology research | $3,649,842 |
| ICON GOVERNMENT AND PUBLIC HEALTH SOLUTI Biotechnology research | $2,668,810 |
| REDMEDED LLC Continuing medical education | $1,393,824 |
| RELEVATE HEALTH GROUP LLC Marketing consultant | $950,116 |
| EVEREST CLINICAL RESEARCH CORPORATION Biotechnology research | $910,373 |
Individuals listed as contractors are left out. 34 contractors were paid more than $100,000 in all.
Private foundation grants it received
43 private foundations reported grants to The Multiple Myeloma Research Foundation totaling $492K on their tax year 2023 Form 990-PF returns. See which foundations, on WHOFUNDS.
Source: WHOFUNDS open grant graph, matched from Form 990-PF Part XV.
Correct a figure or respond
Every number above is copied from The Multiple Myeloma Research Foundation's own Form 990. If one doesn't match the filing, that's our error and we'll fix it. If you work for The Multiple Myeloma Research Foundation, you can publish a response that is linked from this page.
Share or embed this breakdown
Of every $100 The Multiple Myeloma Research Foundation spent in 2025, $78.94 went to programs. The full breakdown, from its IRS Form 990:
Embed on your site
Similar-sized charities in this cause
- Lifelong Health for AllSeattle, WA · revenue $36M · programs 85.3% · 2024
- Ladacin NetworkWanamassa, NJ · revenue $37M · programs 95.3% · FY2025
- AIDS Action Coalition of HuntsvilleHuntsville, AL · revenue $36M · programs 95.2% · FY2025
- Colorado Health NetworkDenver, CO · revenue $37M · programs 94.0% · FY2025
- American Osteopathic AssociationChicago, IL · revenue $36M · programs 60.7% · FY2025
All diseases, disorders & medical disciplines charities · Largest charities in Connecticut
Questions people ask
How much of The Multiple Myeloma Research Foundation's spending goes to programs?
In calendar year 2025, The Multiple Myeloma Research Foundation reported that 78.9% of its $34.7 million in expenses went to program services, 3.4% to management and general and 17.6% to fundraising (Form 990, Part IX).
How much does The Multiple Myeloma Research Foundation pay its top executive?
The largest total compensation The Multiple Myeloma Research Foundation reported for one person in calendar year 2025 was $568,410, for the role of PRESIDENT & CEO (Form 990, Part VII, including compensation from related organizations and other compensation).
Where does The Multiple Myeloma Research Foundation get its money?
Of $36.5 million in revenue in calendar year 2025, 72.9% came from contributions and grants and 23.8% from program service revenue (Form 990, Part VIII).
Is The Multiple Myeloma Research Foundation a registered charity?
The IRS lists EIN 06-1504413 as a 501(c)(3) organization (publicly supported organization (170(b)(1)(a)(vi))), and its records show contributions as tax-deductible. Form 990 filings on record here cover tax years 2019, 2020, 2021, 2022, 2023, 2024, 2025. A filing shows what the organization reported; it doesn't by itself show whether a program works.
Sources
- 2025: Form 990 for calendar year 2025, object 202632379349301803 · read the filing
- 2024: Form 990 for calendar year 2024, object 202512889349301411 · read the filing
- 2023: Form 990 for calendar year 2023, object 202422689349300902 · read the filing
- 2022: Form 990 for calendar year 2022, object 202313039349302071 · read the filing
- 2021: Form 990 for calendar year 2021, object 202233129349303178 · read the filing
- 2020: Form 990 for calendar year 2020, object 202112599349300941 · read the filing
- 2019: Form 990 for calendar year 2019, object 202042749349301569 · read the filing
All filings for EIN 06-1504413: ProPublica Nonprofit Explorer · IRS Tax Exempt Organization Search. Figures are as the organization reported them; we have not audited them.